Best practice for restoration of stone reefs in Denmark (codes of conduct) 2013

This report includes recommendations for all phases of a boulder reef restoration project. The document includes an initial identification of relevant objectives for restoration, public involvement and identifies possible sources of relevant historic information as well as risks to be considered. A set of specific biological and environmental objectives that can influence the choice of design of the new reef structure is also presented. The report also includes a set of recommendations for the construction phase, requirements for safety navigation when the restoration work is finalized and presents suggestions for monitoring and management effort

Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms

Rinitis al·lèrgica; Costos; MedicamentsRinitis alérgica; Costos; MedicamentosAllergic rhinitis; Costs; MedicationsBackground The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. Methods We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS®—Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking—OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). Results Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. Discussion There are major differences between countries in terms of rhinoconjunctivitis medication usage

Demokratisk dannelse til aktivt interkulturelt medborgerskab

Indholdssiden i fremmedsprogsfagene har længe været fokuseretpå den kulturelle..